Drugs that contain Vutrisiran

1. Drug name - AMVUTTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(5 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(12 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(13 years from now)

CN102006890A ALNYLAM PHARMS INC Targeting Lipid
Oct, 2015

(7 years ago)

EP2231194A2 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

EP2231195B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231195A2 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP3156077B1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

EP2231194B1 ALNYLAM PHARMS INC Folate-Irna Conjugates
Dec, 2028

(5 years from now)

EP3156077A1 ALNYLAM PHARMS INC Targeting Lipids
Dec, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027

Market Authorisation Date: 13 June, 2022

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
25MG/0.5ML (25MG/0.5ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.